In any event, here is the latest, from Endpoint News' fine reporting -- do go read it all (behind a paywall, though):
. . .Merck said on Thursday that it will participate “under protest” in the first round of price negotiations with the Centers for Medicare and Medicaid Services for its type 2 diabetes treatment Januvia (sitagliptin).
The company is the fourth to announce that it will agree to the IRA's Medicare negotiations process, ahead of the October 1 deadline. . . .
Just as we predicted several months ago, when the strike suits were first filed. Yawn. And. . . onward!
नमस्ते
No comments:
Post a Comment